Temozolomide with or without olaparib for triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a chemotherapy drug (temozolomide) alone or combined with a targeted therapy (olaparib) for people with triple negative breast cancer. It may help if your tumor has a specific genetic marker (MGMT promoter methylation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple negative breast cancer that has spread and have had at least one round of chemotherapy for metastatic disease.
- Your tumor must have a specific change called MGMT promoter methylation, which the study will test for.
- You must have tumor tissue available for testing, or be willing to have a new biopsy.
- You must have received treatment with anthracyclines and taxanes in the past.
- You are 18 or older and in generally good health (able to care for yourself).
- If you have had brain metastases, they must be treated and stable without steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called olaparib (a PARP inhibitor) in people with triple-negative breast cancer that has returned or spread, and whose tumors do not have a BRCA gene mutation but do have a change called BRCA1 promoter methylation. The goal is to see if olaparib can help shrink or slow the cancer, based on this specific tumor feature.
This study tests a combination of two drugs — an immunotherapy (QL1706) and a PARP inhibitor (olaparib) — to see if it can help people with triple-negative breast cancer that has come back or spread, especially when their tumors have a specific DNA repair problem (HRD). It is for people who have already tried at least one prior treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
Hear when a new Breast Cancer Triple Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.